Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Pharmaceuticals - NEC
12:31pJOHNSON & JOHNSON : J&J beats quarterly expectations on drug sales surge, shares..
RE
12:30pJOHNSON & JOHNSON : Pharma Business Fuels Sales Growth -- Update
DJ
11:56aJohnson & Johnson on Track for Largest Intraday Percent Increase Since Jan 20..
DJ
09:30aABBVIE : Signs Humira Patent License with Mylan
DJ
08:16aJOHNSON & JOHNSON : Pharmaceuticals Business Delivers, but Company Lowers Sales ..
DJ
03:05aInvestor 2Q Net Profit Rises 34%
DJ
02:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/16J&J'S JANSSEN : Credence Trial of Invokana Being Stopped Early for Positive Effi..
DJ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/16SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/13INDIVIOR : wins preliminary injunction against generic rival
RE
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13JOHNSON & JOHNSON : J&J vows to overturn $4.7 billion talc verdict but experts s..
RE
07/13Vattenfall Signs Wind-Energy Deal With Novo Nordisk, Novozymes
DJ
07/13JOHNSON & JOHNSON : J&J Is Hit by $4.7 Billion Verdict -- WSJ
DJ
07/12JOHNSON & JOHNSON : Jury orders J&J to pay $4.7 billion in Missouri asbestos can..
RE
07/12JOHNSON & JOHNSON : Jury orders J&J to pay $4.7 billion in Missouri asbestos can..
RE
07/12JOHNSON & JOHNSON : J&J Hit With $4.7 Billion Jury Verdict in Baby Powder Suit -..
DJ
07/12JOHNSON & JOHNSON : J&J Hit With $550 Million Jury Verdict in Baby Powder Suit
DJ
07/12GLAXOSMITHKLINE : Sells Tapinarof Rights for Up to GBP250 Million
DJ
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
DJ
07/12ABBOTT LABORATORIES : Labs Gets FDA Approval for MitraClip for Leaky Heart Valve..
DJ
07/12Lanxess water treatment unit attracts interest - sources
RE
07/12South Korea regulator says Samsung BioLogics violated accounting rules
RE
07/12Exclusive - With U.S. trade under a cloud, China opens to Indian pharma
RE
07/12PFIZER : Plans To Shuffle Its Divisions -- WSJ
DJ
07/12SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/11LIGAND PHARMACEUTICALS : Janssen Enter R&D Deal
DJ
07/11PFIZER : Trump told Pfizer CEO price hikes hurt his drug plan - source
RE
07/11Brazil prosecutors allege jailed GE executive helped company partake in medic..
RE
07/11PFIZER : separates consumer health unit in business rejig
RE
07/11ABBVIE : Says Study of Imbruvica in Type of Lymphoma Didn't Meet Primary Endpoin..
DJ
07/11PFIZER : to Reorganize Business Units
DJ
07/11MERCK AND : Keytruda Gets FDA Priority Review in Liver Cancer
DJ
07/11Indivior warning on anti-opioid drug competition sends shares tumbling
RE
07/11PFIZER : Backs Off on Raising Drug Prices -- WSJ
DJ
07/11SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/10PFIZER : to Roll Back Price Increases After Trump Criticism--2d Update
DJ
07/10PFIZER : delays drug price hikes after talking with Trump
RE
07/10PFIZER : delays drug price hikes after talking with Trump
RE
07/10PFIZER : to Roll Back Price Increases After Trump Criticism--Update
DJ
07/10PFIZER : to Roll Back Price Increases After Trump Criticism
DJ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
07/10BAYER : U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial
RE
07/10Canopy Growth to buy Tokyo Smoke owner Hiku Brands for C$269.2 million
RE
07/10PACIRA PHARMACEUTICALS : Preliminary 2Q Exparel Net Product Sales Up 15%
DJ
07/10SANOFI : France launches 100 million euros biotech fund
RE
07/10TAKEDA PHARMACEUTICAL : Japan's Takeda gains U.S. approval for $62 billion Shire..
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 52 100 M
EBIT 2018 12 767 M
Net income 2018 9 303 M
Debt 2018 13 415 M
Yield 2018 3,73%
P/E ratio 2018 16,22
P/E ratio 2019 19,44
EV / Sales 2018 4,12x
EV / Sales 2019 3,97x
Capitalization 201 B
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVARTIS-4.54%201 464
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
ROCHE HOLDING LTD.-5.78%201 132
MERCK AND COMPANY11.23%169 193
AMGEN12.66%129 635
ABBOTT LABORATORIES10.50%110 556
SANOFI-0.26%105 236
GLAXOSMITHKLINE17.82%103 541
BAYER-8.97%102 038
ELI LILLY AND COMPANY6.22%97 374
NOVO NORDISK A/S-5.56%95 085
BRISTOL-MYERS SQUIBB COMPANY-7.21%92 940
ASTRAZENECA6.76%92 217
CELGENE CORPORATION-17.89%62 110
ALLERGAN PLC8.30%60 065
SHIRE10.87%52 493
JIANGSU HENGRUI MEDICINE CO LTD40.80%41 196
TAKEDA PHARMACEUTICAL CO LTD-27.83%33 152
ASTELLAS PHARMA INC22.86%31 366
EISAI CO., LTD67.31%28 668